GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (NYSE:CNMD) » Definitions » Piotroski F-Score

CNMD (Conmed) Piotroski F-Score : 9 (As of Jul. 08, 2025)


View and export this data going back to 1987. Start your Free Trial

What is Conmed Piotroski F-Score?

Good Sign:

Piotroski F-Score is 9, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Conmed has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Conmed's Piotroski F-Score or its related term are showing as below:

CNMD' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 9

During the past 13 years, the highest Piotroski F-Score of Conmed was 9. The lowest was 3. And the median was 6.


Conmed Piotroski F-Score Historical Data

The historical data trend for Conmed's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conmed Piotroski F-Score Chart

Conmed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 4.00 6.00 9.00

Conmed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 9.00 9.00 9.00

Competitive Comparison of Conmed's Piotroski F-Score

For the Medical Devices subindustry, Conmed's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conmed's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Conmed's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Conmed's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was 29.976 + 48.984 + 33.755 + 6.036 = $119 Mil.
Cash Flow from Operations was 43.306 + 51.203 + 43.338 + 41.534 = $179 Mil.
Revenue was 332.097 + 316.701 + 345.944 + 321.256 = $1,316 Mil.
Gross Profit was 183.729 + 178.995 + 198.344 + 177.752 = $739 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(2309.255 + 2285.616 + 2315.744 + 2306.247 + 2297.683) / 5 = $2302.909 Mil.
Total Assets at the begining of this year (Mar24) was $2,309 Mil.
Long-Term Debt & Capital Lease Obligation was $891 Mil.
Total Current Assets was $639 Mil.
Total Current Liabilities was $283 Mil.
Net Income was 13.732 + 15.837 + 33.071 + 19.709 = $82 Mil.

Revenue was 317.652 + 304.578 + 327.045 + 312.273 = $1,262 Mil.
Gross Profit was 170.69 + 168.059 + 182.175 + 171.965 = $693 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(2320.12 + 2322.722 + 2325.675 + 2300.021 + 2309.255) / 5 = $2315.5586 Mil.
Total Assets at the begining of last year (Mar23) was $2,320 Mil.
Long-Term Debt & Capital Lease Obligation was $990 Mil.
Total Current Assets was $636 Mil.
Total Current Liabilities was $291 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Conmed's current Net Income (TTM) was 119. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Conmed's current Cash Flow from Operations (TTM) was 179. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=118.751/2309.255
=0.05142394

ROA (Last Year)=Net Income/Total Assets (Mar23)
=82.349/2320.12
=0.03549342

Conmed's return on assets of this year was 0.05142394. Conmed's return on assets of last year was 0.03549342. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Conmed's current Net Income (TTM) was 119. Conmed's current Cash Flow from Operations (TTM) was 179. ==> 179 > 119 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=891.443/2302.909
=0.38709432

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=990.11/2315.5586
=0.42759013

Conmed's gearing of this year was 0.38709432. Conmed's gearing of last year was 0.42759013. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=639/283.148
=2.25677031

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=635.724/291.404
=2.18158982

Conmed's current ratio of this year was 2.25677031. Conmed's current ratio of last year was 2.18158982. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Conmed's number of shares in issue this year was 31.151. Conmed's number of shares in issue last year was 31.272. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=738.82/1315.998
=0.56141423

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=692.889/1261.548
=0.54923713

Conmed's gross margin of this year was 0.56141423. Conmed's gross margin of last year was 0.54923713. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=1315.998/2309.255
=0.5698799

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=1261.548/2320.12
=0.54374257

Conmed's asset turnover of this year was 0.5698799. Conmed's asset turnover of last year was 0.54374257. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+1
=9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Conmed has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

Conmed  (NYSE:CNMD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Conmed Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Conmed's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Conmed Business Description

Traded in Other Exchanges
Address
11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Executives
Charles Farkas director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Peters Stanley W Iii officer: VP GM General Surgery C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
David M Bronson director
Barbara J Schwarzentraub director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Martha Goldberg Aronson director 40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Pat Beyer officer: President-Conmed International C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Todd W. Garner officer: Executive Vice President & CFO C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Edward A. Clifford officer: VP Global Manufacturing C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Curt R Hartman director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John D. Ferrell officer: Executive Vice President - HR C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Brian Concannon director HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144
Daniel Jonas officer: Vice President/Legal Affairs, other: General Counsel C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Terence M Berge officer: VP Corp. Treasurer C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Peter K Shagory officer: EVP,STRAT & CORP DEVT C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Johonna Marie Pelletier officer: Treasurer and VP, Tax C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773